Loading...

Commercial Pharma And GLP-1 Expansion Will Empower Future Progress

Published
06 Apr 25
Updated
17 Sep 25
AnalystConsensusTarget's Fair Value
R120.60
15.5% undervalued intrinsic discount
17 Sep
R101.87
Loading
1Y
-46.3%
7D
-1.6%

Author's Valuation

R120.6

15.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on17 Sep 25
Fair value Decreased 2.43%

Aspen Pharmacare Holdings' consensus price target has decreased to ZAR120.60, reflecting concerns over a sharply higher future P/E and a substantial decline in net profit margin. What's in the News Aspen Pharmacare Holdings Limited announced an annual dividend of ZAR 2.1100 per share.

Shared on01 May 25
Fair value Decreased 21%

Shared on23 Apr 25
Fair value Decreased 21%

AnalystConsensusTarget has decreased revenue growth from 8.1% to 5.8% and decreased profit margin from 17.7% to 13.9%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 63%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.